Meeting
2023 ASCO Annual Meeting
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
Authors
Antoine Desilets
Memorial Sloan Kettering Cancer Center, New York, NY
Antoine Desilets , David G. Pfister , Winston Wong , Eric Jeffrey Sherman , James Vincent Fetten , Kin Wai (Tony) Hung , Lara Dunn , Alan Loh Ho , Loren S. Michel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03667482
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6025)
DOI
10.1200/JCO.2023.41.16_suppl.6025
Abstract #
6025
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
First Author: Ye Guo
Poster
2017 ASCO Annual Meeting
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman
Poster
2013 ASCO Annual Meeting
Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.
First Author: Nabil F. Saba
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu